Response in the placebo group in randomized controlled trials for moderate-to-severe psoriasis

被引：0
|
作者：
Afach, Sivem [1 ]
Le Cleach, Laurence [1 ,2 ]
Sbidian, Emilie [1 ,2 ]
机构：
[1] Univ Paris Est Creteil, UPEC EpiDermE EA, Creteil, France
[2] UPEC, Hop Univ Henri Mondor, AP HP, Dept Dermatol, Creteil, France
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
32102
引用
收藏
页码：AB103 / AB103
页数：1
相关论文
共 50 条
  • [21] Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
    Wang, Yuqian
    Li, Sheng
    Bai, Juan
    Cai, Xiaoxuan
    Tang, Shunli
    Lin, Peiyi
    Sun, Qingmiao
    Qiao, Jianjun
    Fang, Hong
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14
  • [22] Deucravacitinib in moderate-to-severe psoriasis
    Vu, Alan
    Maloney, Victoria
    Gordon, Kenneth B.
    IMMUNOTHERAPY, 2022, 14 (16) : 1279 - 1290
  • [23] Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study
    Nemoto, O.
    Hirose, K.
    Shibata, S.
    Li, K.
    Kubo, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (03) : 689 - 696
  • [24] A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
    Papp, K. A.
    Reich, K.
    Paul, C.
    Blauvelt, A.
    Baran, W.
    Bolduc, C.
    Toth, D.
    Langley, R. G.
    Cather, J.
    Gottlieb, A. B.
    Thaci, D.
    Krueger, J. G.
    Russell, C. B.
    Milmont, C. E.
    Li, J.
    Klekotka, P. A.
    Kricorian, G.
    Nirula, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (02) : 273 - 286
  • [25] Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)
    Gyldenlove, Mette
    Meteran, Howraman
    Sorensen, Jennifer A.
    Fage, Simon
    Yao, Yiqiu
    Lindhardsen, Jesper
    V. Nissen, Christoffer
    Todberg, Tanja
    Thomsen, Simon F.
    Skov, Lone
    Zachariae, Claus
    Iversen, Lars
    Nielsen, Mia -Louise
    Egeberg, Alexander
    LANCET REGIONAL HEALTH-EUROPE, 2023, 30
  • [26] Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study
    Prajapati, Vimal H.
    Seyger, Marieke M. B.
    Wilsmann-Theis, Dagmar
    Szakos, Erzsebet
    Kaszuba, Andrzej
    van Hartingsveldt, Bart
    Jett, Meg
    Jiang, Gigi
    Li, Shu
    Sinha, Vikash
    Crauwels, Herta
    Deklotz, Cynthia M. C.
    Paller, Amy S.
    BRITISH JOURNAL OF DERMATOLOGY, 2025, 192 (04) : 618 - 628
  • [27] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Reply
    Gordon, Kenneth B.
    Colombel, Jean-Frederic
    Hardin, Dana S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2102 - 2102
  • [28] Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    Cyrille, Marcoli
    Hansen, Mark Berner
    Feagan, Brian G.
    Loftus, Edward V., Jr.
    Rogler, Gerhard
    Vermeire, Severine
    Cruz, Martha L.
    Yang, Jun
    Boedigheimer, Michael J.
    Abuqayyas, Lubna
    Evangelista, Christine M.
    Sullivan, Barbara A.
    Reinisch, Walter
    GASTROENTEROLOGY, 2019, 156 (04) : 946 - +
  • [29] Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials
    Egeberg, Alexander
    Conrad, Curdin
    Gorecki, Patricia
    Wegner, Sven
    Buyze, Jozefien
    Acciarri, Lorenzo
    Thaci, Diamant
    DERMATOLOGY AND THERAPY, 2024, 14 (3) : 745 - 758
  • [30] Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials
    Alexander Egeberg
    Curdin Conrad
    Patricia Gorecki
    Sven Wegner
    Jozefien Buyze
    Lorenzo Acciarri
    Diamant Thaçi
    Dermatology and Therapy, 2024, 14 : 745 - 758
12345